<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406002</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-045</org_study_id>
    <secondary_id>2009-015763-13</secondary_id>
    <nct_id>NCT01406002</nct_id>
  </id_info>
  <brief_title>To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)</brief_title>
  <official_title>An Open-label, One-sequence Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Pharmacokinetics of YM150 (Darexaban) and Metabolites in Young Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effect of rifampicin on the way the
      body handles darexaban and its metabolites (drug degradation products). The secondary
      objective of the study is to evaluate the safety and tolerability of a single dose of
      darexaban alone and when administered together with rifampicin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, 1-sequence study in young healthy male subjects to evaluate the effect
      of multiple daily doses of rifampicin on the PK of darexaban and metabolites after a single
      dose of darexaban. In addition, safety and tolerability of darexaban administered alone and
      in combination with rifampicin is evaluated. Eligible subjects are admitted to the clinical
      unit in the morning of Day -1.

      Subjects receive a single dose of darexaban on Day 1. Subjects then receive rifampicin once
      daily (qd) on Days 4-14.On Day 11, the second single dose of darexaban is given in
      combination with rifampicin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of darexaban and its metabolites assessed by plasma concentration</measure>
    <time_frame>Plasma samples are taken until 72 hours after darexaban dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pharmacokinetics of Darexaban and Metabolites</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>darexaban, wash-out, rifampicin + darexaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darexaban</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <other_name>YM150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 18.5-30.0 kg/m2

          -  Male subjects must be non-fertile, i.e. surgically sterilized or must practice an
             adequate contraceptive method to prevent pregnancies

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to darexaban or rifampicin or any components of
             the formulation used

          -  Any of the liver function tests (i.e. ALT and AST) above the upper limit of normal at
             repeated measures

          -  Any clinically significant history of any other disease or disorder -
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,
             dermatological, psychiatric or metabolic as judged by the medical investigator

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  Use of any prescribed or OTC drugs (including vitamins, natural and herbal remedies,
             e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except
             for occasional use of paracetamol (up to 3 g/day)

          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the
             3 months prior to admission to the Clinical Unit

          -  Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or
             more than 21 units (210 g) of alcohol per week within the 3 months prior to study
             Donation of blood or blood products within 3 months prior to admission to the Clinical
             Unit

          -  Participation in any clinical study within 3 months or participation in more than 3
             clinical studies within 12 months, prior to the expected date of enrolment into the
             study, provided that the clinical study did not entail a biological compound with a
             long terminal half life
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prinicpal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Aster, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=568</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013 Feb;75(2):440-9. doi: 10.1111/j.1365-2125.2012.04346.x.</citation>
    <PMID>22642721</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>darexaban</keyword>
  <keyword>YM150</keyword>
  <keyword>rifampicin</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Darexaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

